Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Onchocerciasis Treatment Market Grown from 2024 to 2025?

In recent times, the onchocerciasis treatment industry has experienced significant growth. The market size is projected to expand from $1.03 billion in 2024 to about $1.11 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.8%. A surge in the number of individuals dealing with vision-related problems, a rise in parasitic infections, an escalated number of specialized treatment facilities, improved awareness through education campaigns, and the increase in the elderly population contribute to this historical growth.

What Growth Rate Is Anticipated for the Onchocerciasis Treatment Market in the Coming Years?

The market for onchocerciasis treatment is projected to witness substantial expansion in the approaching years, rising to a worth of $1.48 billion in 2029 with a 7.5% Compound Annual Growth Rate (CAGR). Factors contributing to this growth during the forecast period include a surge in prevalence in areas where the disease is endemic, an increased demand for surgical procedures, an enhancement in healthcare facilities, an upsurge in chronic diseases, and increased investment in healthcare. The forecast period will also see major trends such as a move towards single-dose treatment plans, advancements in macrocyclic lactone formulations, the rise of therapies targeting Wolbachia, integration of artificial intelligence in drug discovery, and the culmination of treatments specifically designed for children.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

Who Are the Leading Companies in the Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

What Are the Key Drivers of the Onchocerciasis Treatment Market?

An increase in people suffering from eye-related problems is anticipated to pave the way for the expansion of the onchocerciasis treatment market. Eye-related issues encompass a range of conditions impacting vision and eye health, such as infections, injuries, and chronic diseases like cataracts or glaucoma. The surge in these issues is predominantly due to extended screen time and long-lasting exposure to digital devices. Treatments for onchocerciasis aid in staving off and managing vision impairment and blindness in patients by eradicating the parasitic infection leading to inflammation and harm to ocular tissues. For example, the Centers for Disease Control and Prevention (CDC), a United States-based public health institution, reported in May 2024 that roughly 20.5 million Americans aged 40 and above suffered from cataracts in at least one eye, making up 17.2% of that demographic. By 2028, it is projected that nearly 30 million individuals will be affected by cataracts. Therefore, the growing occurrence of eye-related health conditions fuels the growth of the onchocerciasis treatment market. The Growing Incidence of Surgical Interventions Spurs Market Growth due to Increasing Instances Requiring Advanced Disease Control

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24634&type=smp

What Are the Key Market Segments in the Onchocerciasis Treatment Industry?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

What Are the Latest Trends in the Onchocerciasis Treatment Market?

Leading corporations in the onchocerciasis treatment sector are concentrating on the creation of unique antiparasitic drugs to enhance the efficacy of treatments and decrease their duration. These are drugs formulated to eradicate or deter parasites like worms and protozoa, which result in human infections. For example, in December 2024, Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical firm based in Australia, obtained Ghana Food and Drugs Authority’s (FDA) authorization for 2 mg Moxidectin oral tablets to cure river blindness in people who are 4 years old and above. The go-ahead allows Ghana to run community-based mass drug distribution programmes featuring moxidectin, providing higher potency and enduring effect in comparison to ivermectin. MDGH intends to increase availability to a new efficient onchocerciasis treatment through this approval, facilitating large-scale community operations in regions where the disease is prevalent.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

What Are the Key Regional Markets in the Onchocerciasis Treatment Industry?

North America was the largest region in the onchocerciasis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24634

This Report Delivers Insight On:

1. How big is the onchocerciasis treatment market, and how is it changing globally?

2. Who are the major companies in the onchocerciasis treatment market, and how are they performing?

3. What are the key opportunities and risks in the onchocerciasis treatment market right now?

4. Which products or customer segments are growing the most in the onchocerciasis treatment market?

5. What factors are helping or slowing down the growth of the onchocerciasis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model